In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will ...

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect ...

As AI reshapes deeply specialized scientific work, R&D professionals must learn to navigate the shift to a skills-centered ...

Convergent Therapeutics' Dr. Philip Kantoff and Plus Therapeutics' Dr. Marc Hedrick discuss how unmet medical needs, maturing ...

Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more ...

Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that ...

Serial biotech investor Kevin Tang previously unsuccessfully tried to buy Kezar Life Sciences via Concentra Biosciences, a ...

Kenneth Munie is a senior managing director leading Accenture’s products industry strategy practice globally, overseeing ...